Novavax (NASDAQ:NVAX) : On Wednesday, The money flowed into the Novavax (NASDAQ:NVAX) stock with an uptick to downtick ratio was recorded at 1.67. Transactions worth $1.47 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $0.88 million. The total money flow into the stock was $0.59 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $0.38 million of block transactions on upticks. The total money flow in block trades was $0.38 million. In terms of price action, Novavax (NASDAQ:NVAX) traded down $0.04 during the session at $6.93. Compared to the previous days closing, the stock was down only by -0.57%. For the week, the stock is 4.05%, over previous weeks closing.
In an insider trading activity,The director of Novavax Inc, Evans Gary C sold 18,998 shares at $6.5 on June 6, 2016. The Insider selling transaction had a total value worth of $123,487. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. Currently the company Insiders own 3.5% of Novavax shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -17.65% . Institutional Investors own 82% of Novavax shares. During last six month period, the net percent change held by insiders has seen a change of -16.33%.
The company shares have dropped -36.64% from its 1 Year high price. On Aug 11, 2015, the shares registered one year high at $15.01 and the one year low was seen on Feb 3, 2016. The 50-Day Moving Average price is $5.96 and the 200 Day Moving Average price is recorded at $5.80. Novavax (NASDAQ:NVAX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.09 and $6.90 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.25. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.17, notching a gain of 2.87% for the day. The total traded volume was 6,779,385 . The stock had closed at $6.97 on the previous day.
Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).